KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to 19.69%.

  • Teva Pharmaceutical Industries' EBITDA Margin rose 2086.00% to 19.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.89%, marking a year-over-year increase of 802.00%. This contributed to the annual value of -1.83% for FY2024, which is 456.00% down from last year.
  • As of Q3 2025, Teva Pharmaceutical Industries' EBITDA Margin stood at 19.69%, which was up 80.69% from 10.90% recorded in Q2 2025.
  • Teva Pharmaceutical Industries' EBITDA Margin's 5-year high stood at 19.69% during Q3 2025, with a 5-year trough of -25.54% in Q2 2022.
  • Moreover, its 3-year median value for EBITDA Margin was -0.12% (2024), whereas its average is 4.08%.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' EBITDA Margin spiked by 12,518bps in 2021, and later tumbled by 4,043bps in 2022.
  • Teva Pharmaceutical Industries' EBITDA Margin (Quarterly) stood at 1.90% in 2021, then slumped by 2,610bps to -24.20% in 2022, then skyrocketed by 4,116bps to 16.96% in 2023, then crashed by 1,765bps to -0.69% in 2024, then soared by 2,086bps to 19.69% in 2025.
  • Its EBITDA Margin was 19.69% in Q3 2025, compared to 10.90% in Q2 2025 and 13.34% in Q1 2025.